The latest price target for Catalyst Pharmaceuticals (NASDAQ:CPRX) was reported by Stephens & Co. on November 18, 2024. The analyst firm set a price target for $35.00 expecting CPRX to rise to within 12 months (a possible 65.88% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ:CPRX) was provided by Stephens & Co., and Catalyst Pharmaceuticals initiated their overweight rating.

There is no last upgrade for Catalyst Pharmaceuticals

The last downgrade for Catalyst Pharmaceuticals Inc happened on August 24, 2022 when Roth Capital changed their price target from $10 to $15.5 for Catalyst Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a initiated with a price target of $0.00 to $35.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $21.10, which is within the analyst’s predicted range.